{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:52:19Z","timestamp":1790974339876,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer Global Research & Development"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ejphar.2011.09.034","type":"journal-article","created":{"date-parts":[[2011,9,22]],"date-time":"2011-09-22T03:37:39Z","timestamp":1316662659000},"page":"347-355","source":"Crossref","is-referenced-by-count":3,"title":["In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V1A receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245)"],"prefix":"10.1016","volume":"670","author":[{"given":"Rachel","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Attkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Weibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Bictash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevie","family":"Neal-Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ivarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.09.034_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.1994.tb21735.x","article-title":"Vascularization of human endometrium, Uterine blood flow in healthy condition and in primary dysmenorrhoea","volume":"734","author":"Akerlund","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0010","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ki.2009.319","article-title":"Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice","volume":"76","author":"Aoyagi","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1254\/jphs.08R17FM","article-title":"New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia","volume":"109","author":"Arai","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.npp.1300360","article-title":"Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice","volume":"29","author":"Bielsky","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00213-008-1354-x","article-title":"Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior","volume":"202","author":"Bleickardt","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1471-0528.1997.tb11500.x","article-title":"Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions","volume":"104","author":"Bossmar","year":"1997","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1471-0528.2000.tb13302.x","article-title":"Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea","volume":"107","author":"Brouard","year":"2000","journal-title":"BJOG"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0040","doi-asserted-by":"crossref","first-page":"e5129","DOI":"10.1371\/journal.pone.0005129","article-title":"A hypomorphic vasopressin allele prevents anxiety-related behavior","volume":"4","author":"Bunck","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/clpt.2008.217","article-title":"Vascular effects of RWJ-676070, a selective combined V1a\/V2 vasopressin receptor antagonist","volume":"85","author":"Coltamai","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0050","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","article-title":"Non-peptide arginine-vasopressin antagonists: the vaptans","volume":"371","author":"Decaux","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1254\/jphs.08R14FM","article-title":"New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions","volume":"109","author":"Egashira","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0060","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1471-0528.1992.tb13855.x","article-title":"Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment\u2013effect on uterine contractility","volume":"99","author":"Ekstrom","year":"1992","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0065","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/13543780903066764","article-title":"Investigational vasopressin receptor modulators in the pipeline","volume":"18","author":"Favory","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0070","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0075","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.amjmed.2006.05.015","article-title":"Is there a cardiovascular rationale for the use of combined vasopressin V1a\/V2 receptor antagonists?","volume":"119","author":"Goldsmith","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0080","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","article-title":"Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders","volume":"99","author":"Griebel","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejphar.2008.06.010","article-title":"Pharmacological characterization of RWJ-676070, a dual vasopressin V1A\/V2 receptor antagonist","volume":"590","author":"Gunnet","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1677\/joe.0.1150355","article-title":"Plasma concentrations of vasopressin and a prostaglandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with a combined oral contraceptive","volume":"115","author":"Hauksson","year":"1987","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0095","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1471-0528.1988.tb06577.x","article-title":"Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist","volume":"95","author":"Hauksson","year":"1988","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/39.10.1132","article-title":"Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon","volume":"39","author":"Hayoz","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10928-006-9035-z","article-title":"Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model","volume":"34","author":"Jacqmin","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0220","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/jpet.111.178848","article-title":"Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension","volume":"337","author":"Laporte","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0115","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00018-006-6054-2","article-title":"Vasopressin antagonists","volume":"63","author":"Lemmens-Gruber","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0165-6147(00)89066-5","article-title":"Analysis of competitive agonist\u2013antagonist interactions by nonlinear regression","volume":"16","author":"Lew","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/00016340500495082","article-title":"Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea","volume":"85","author":"Liedman","year":"2006","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/09513590802306218","article-title":"Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects","volume":"24","author":"Liedman","year":"2008","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.neuint.2011.01.018","article-title":"Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury","volume":"58","author":"Manaenko","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0140","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1523\/JNEUROSCI.1614-04.2004","article-title":"Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety","volume":"24","author":"Murgatroyd","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0145","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.clinthera.2010.06.015","article-title":"Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review","volume":"32","author":"Nemerovski","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cvr\/cvq034","article-title":"Decreased susceptibility to salt-induced hypertension in subtotally nephrectomized mice lacking the vasopressin V1a receptor","volume":"87","author":"Oikawa","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0155","first-page":"538","article-title":"Modulation of the vasopressin system for the treatment of CNS diseases","volume":"13","author":"Ryckmans","year":"2010","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-1-4615-4871-3_44","article-title":"Molecular aspects of vasopressin receptor function","volume":"449","author":"Schoneberg","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI116554","article-title":"Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors","volume":"92","author":"Serradeil-Le Gal","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0165","first-page":"53","article-title":"An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders","volume":"11","author":"Serradeil-Le Gal","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/j.1600-0412.2004.00320.x","article-title":"Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women","volume":"83","author":"Steinwall","year":"2004","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0175","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/09513590400021144","article-title":"The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor","volume":"20","author":"Steinwall","year":"2005","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/00016348409156715","article-title":"Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea","volume":"63","author":"Stromberg","year":"1984","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vph.2005.01.002","article-title":"Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist","volume":"42","author":"Tsukada","year":"2005","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0225","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.drudis.2010.08.001","article-title":"Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents","volume":"15","author":"Veeraveedu","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0205","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/01.HYP.30.5.1121","article-title":"Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans","volume":"30","author":"Weber","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2011.09.034_bb0210","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Yung-Chi","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.09.034_bb0215","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","article-title":"Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance","volume":"30","author":"Zhang","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911009988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911009988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T07:11:42Z","timestamp":1712905902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911009988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":43,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0014299911009988"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.09.034","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}